Lumakras
Lumakras-Vectibix combo outperforms standard therapy in KRAS G12C-mutated colorectal cancer (ESMO 2023)
Anika Sharma
ESMO 2023: LBA10 Nevertheless, a shadow has been cast over the KRAS inhibitor due to recent criticisms by FDA advisors. ...
Amgen’s Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now
Anika Sharma
Amgen’s groundbreaking KRAS inhibitor, Lumakras, faced a pivotal moment as the FDA’s Oncologic Drugs Advisory Committee (ODAC) convened to evaluate ...
FDA Identifies ‘Systemic Bias’ in Amgen’s Late-Stage Lumakras Trial Ahead of Adcomm
Anika Sharma
As an FDA advisory committee prepares to deliberate on the data supporting Amgen’s groundbreaking drug Lumakras, a pre-meeting briefing document ...
Amgen Unveils Exciting First-Line KRAS G12C NSCLC Data: Lumakras (Sotorasib) with Chemotherapy Shines at WCLC
Anika Sharma
Amgen has unveiled exciting findings from a segment of the CodeBreaK 101 clinical trial, a Phase 1b study investigating the ...
FDA Convenes Advisors to Assess Full Approval Prospects for Amgen’s Lumakras Amid KRAS Uncertainties
Anika Sharma
Amgen faces a critical juncture with its pioneering KRAS inhibitor, Lumakras, as uncertainties loom over its potential combinability with standard ...
